Published in Haemophilia on January 01, 2008
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus (2015) 1.46
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care (2016) 1.43
Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. Blood Transfus (2011) 0.95
The Effect of Desmopressin on the Amount of Bleeding in Patients Undergoing Coronary Artery Bypass Graft Surgery with a Cardiopulmonary Bypass Pump After Taking Anti-Platelet Medicine. Anesth Pain Med (2016) 0.75
Reversal of thienopyridine-induced platelet dysfunction following desmopressin administration. J Med Toxicol (2013) 0.75
Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 1.67
Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest (2000) 1.60
Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia (2010) 1.59
Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol (1998) 1.49
Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex. Blood (1983) 1.44
Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol (1999) 1.25
Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant. Ann Intern Med (1998) 1.20
Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med (1985) 1.15
The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost (1998) 1.13
Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost (1997) 1.11
Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost (1999) 1.09
Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol (2002) 1.08
Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost (1997) 1.05
Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica (2001) 1.03
Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost (2000) 1.02
The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol (1998) 1.02
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol (2007) 1.02
The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost (2003) 1.00
PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol (1998) 0.99
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost (2009) 0.98
Oxidative stress and platelet activation in homozygous homocystinuria. Circulation (2001) 0.98
Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest (1985) 0.97
Cost of care of haemophilia with inhibitors. Haemophilia (2009) 0.96
Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res (2011) 0.95
Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol (1979) 0.94
An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost (1997) 0.93
The use of antithrombotic drugs in older people. Minerva Med (2002) 0.92
Diabetes, vascular complications and antiplatelet therapy: open problems. Acta Diabetol (2008) 0.91
Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood (1983) 0.90
Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med (1986) 0.89
Magnetic resonance imaging and ultrasound evaluation of "healthy" joints in young subjects with severe haemophilia A. Haemophilia (2013) 0.87
Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol (1999) 0.87
Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol (1999) 0.87
Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol (1997) 0.87
Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol (1996) 0.86
Citizens and family doctors facing awareness and management of traditional cardiovascular risk factors: results from the Global Cardiovascular Risk Reduction Project (Help Your Heart Stay Young Study). Nutr Metab Cardiovasc Dis (2003) 0.86
Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia (2012) 0.84
Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb (1994) 0.84
Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol (1999) 0.84
Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis (2004) 0.84
Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost (1998) 0.84
The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels. Haematologica (2001) 0.83
Relations of left ventricular mass and systolic function to endothelial function and coronary flow reserve in healthy, new discovered hypertensive subjects. J Hum Hypertens (2005) 0.83
Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost (1999) 0.83
Compound heterozygosity (554-589 del, C515-T transition) in the platelet glycoprotein Ib alpha gene in a patient with a severe bleeding tendency. Thromb Haemost (1999) 0.82
Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. Eur J Clin Invest (2007) 0.82
The effect of tiaprofenic acid on uric acid excretion in man. Drugs (1988) 0.81
Renal handling of urea in subjects with persistent azotemia and normal renal function. Kidney Int (1987) 0.81
The role of ADP secretion and thromboxane synthesis in factor VIII binding to platelets. Blood (1983) 0.81
Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke (1998) 0.81
Functionally abnormal monocytes in hypercholesterolemia. Arterioscler Thromb (1993) 0.81
Angiotensin II inhibition with captopril on plasma ADH, PG synthesis, and renal function in humans. Am J Physiol (1986) 0.81
Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study. Gerontology (2001) 0.81
Antiphospholipid syndrome, adrenal failure, dilated cardiomyopathy and chronic hepatitis: an unusual manifestation of multiorgan autoimmune injury? Eur J Endocrinol (1998) 0.81
Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost (2000) 0.81
Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis? Int J Immunopathol Pharmacol (2009) 0.81
Endovascular Thrombolysis in Acute Mesenteric Vein Thrombosis: a 3-year follow-up with the rate of short and long-term sequaelae in 32 patients. Thromb Res (2010) 0.80
G20210A prothrombin gene mutation and other trombophilic polymorphisms in patients with portal or hepatic venous thrombosis. Gastroenterology (2001) 0.80
High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia (1997) 0.80
Hemostatic and metabolic abnormalities in diabetes mellitus. The search for a link. Haematologica (1995) 0.80
Endothelin abnormalities in patients with pulmonary embolism. Chest (1997) 0.80
Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies. Prog Drug Res (1996) 0.79
A G-to-A mutation in IVS-3 of the human gamma fibrinogen gene causing afibrinogenemia due to abnormal RNA splicing. Blood (2000) 0.79
In vitro inhibition by defibrotide of monocyte superoxide anion generation: a possible mechanism for the antithrombotic effect of a polydeoxyribonucleotide-derived drug. Haemostasis (1991) 0.79
A retrovirus carrying the polyomavirus middle T gene induces acute thrombocythemic myeloproliferative disease in mice. J Virol (1988) 0.79
Hypercholesterolemia and platelets. Semin Thromb Hemost (1993) 0.78
Persistent impairment of platelet aggregation following cessation of a short-course dietary supplementation of moderate amounts of N-3 fatty acid ethyl esters. Thromb Haemost (1999) 0.78
Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings. Haematologica (2001) 0.78
ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes. Diabetes Metab Res Rev (1999) 0.78
Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs. Int J Vasc Med (2011) 0.78
Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: an Italian Case-Control Study. Stroke (1998) 0.78
C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives. Arterioscler Thromb Vasc Biol (2000) 0.77
Determining sulfur-containing amino acids by capillary electrophoresis: a fast novel method for total homocyst(e)ine human plasma. Electrophoresis (1999) 0.77
U-46619, a stable analogue of prostaglandin H2, induces retraction of human platelet-rich plasma clots. Thromb Res (1980) 0.77
Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis. Thromb Haemost (2000) 0.77
Effects of angiotensin II on plasma ADH, prostaglandin synthesis, and water excretion in normal humans. Am J Physiol (1985) 0.77
Exposure of fibrinogen receptors on fresh and stored platelets by ADP and epinephrine as single agents and as a pair. Blood (1983) 0.76
The causal role of salt depletion in acute renal failure due to captopril in hypertensive patients with a single functioning kidney and renal artery stenosis. Ren Fail (1987) 0.76
Fibrinogen naples I (B beta A68T) nonsubstrate thrombin-binding capacities. Thromb Res (2001) 0.76
Long-lasting intestinal bleeding in an old patient with multiple mucosal vascular abnormalities and Glanzmann's thrombasthenia: 3-year pharmacological management. J Intern Med (2002) 0.76
Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides. Thromb Res (1982) 0.76
Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy. Thromb Haemost (2012) 0.76
Determination of atherogenesis in apolipoprotein E-knockout mice. Nutr Metab Cardiovasc Dis (2000) 0.76
Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thromb Haemost (2014) 0.76
Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin. Thromb Haemost (2001) 0.75
Relation between PAI-1 gene locus polymorphism and family history of coronary artery disease. Ann Intern Med (1998) 0.75
Platelet fibrinogen binding in familial hypercholesterolemia. Adv Exp Med Biol (1987) 0.75
Idiopathic Budd-Chiari syndrome in a patient with homozygous Factor V Leiden and heterozygous Factor II G20210A mutations. Thromb Res (2000) 0.75
Effects of PGE2 infusion on renal function in normal man before and after angiotensin II inhibition by captopril. Ren Physiol (1987) 0.75
Risk of myocardial infarction in carriers of mutations in the hemochromatosis-associated gene. Thromb Haemost (2000) 0.75
A fast and accurate method for genotyping the angiotensin-converting enzyme I/D polymorphism. Circulation (1998) 0.75
Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. J Hypertens (1998) 0.75
Severe pancytopenia and intrahepatic cholestasis in a patient with a history of Hodgkin's disease. Responsiveness to high-dose pulse steroid therapy and diagnosis of a late relapse. Eur J Intern Med (2001) 0.75
Hypercoagulability and atherothrombosis: clinical suggestions and perspectives. Haematologica (2001) 0.75
[Prevention of venous thromboembolism: how important is it in non-surgical disease?]. Recenti Prog Med (2001) 0.75
Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis. Thromb Res (2001) 0.75
A frameshift mutation in the human fibrinogen Aalpha-chain gene (Aalpha(499)Ala frameshift stop) leading to dysfibrinogen San Giovanni Rotondo. Thromb Haemost (2001) 0.75
Aggregation of human peripheral blood mononuclear cells by calcium ionophore A23187. Comparison with the aggregation of platelets and defective response in Glanzmann's thrombasthenia. Agents Actions (1988) 0.75
Periprocedural management of antithrombotic therapy and open issues in cancer patients. Minerva Anestesiol (2015) 0.75
The antithrombotic potential of the vessel wall. Evidence from studies on patients prone to venous thrombosis. Haematologica (1988) 0.75